Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma Clinical Trial

Official title:

A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00051025
• Other study ID #: L4389-30
• Status: Completed
• Phase: Phase 2
• First received: December 31, 2002
• Last updated: July 7, 2012
• Start date: May 2000
• Est. completion date: September 2006

Study information

• Verified date: July 2012
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.

Other known NCT identifiers

• NCT00005621

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: September 2006
• Est. primary completion date: January 2001
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathological diagnosis of low-grade (indolent), B-cell, non-Hodgkin's lymphoma.

• Positive expression for CD25 of tumor cells in a lymph node biopsy as defined by greater than 20% of malignant cells staining for CD25 by standardized immunohistochemical assay.

• Modified Ann Arbor Stage I, II, III or IV.

• Patients must have received at least two but no more than five prior therapies. One prior therapy must have been cytotoxic chemotherapy and one prior therapy must have been monoclonal antibody therapy. Combination chemotherapy, including regimens used prior to bone marrow transplantation, will count as a single therapy for purposes of eligibility.

• Patients must have bidimensionally measurable disease.

• Patients must be 18 years of age or older.

• An ECOG performance status of 0, 1, or 2.

• Acceptable organ function defined as follows:

• absolute neutrophil count (ANC) > or = to 1,000/mm3, platelet count > or = to 50,000/mm3, Hemoglobin > or = to 8 g/dL;

• Bilirubin < or = to 1.5 times the upper limit of normal (ULN);

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < or = to 1.5 times the upper limit of normal;

• Serum creatinine <1.8mg/dL;

• Serum albumin > or = to 3.0 g/dL.

• New York Heart Association classification of I or II and no history of poorly controlled hypertension.

• Must be free of serious concurrent illness.

• Female patients must meet the following criteria:

• If the patient is a female of childbearing potential, she must have negative serum beta human chorionic gonadotropin (B-hCG) pregnancy test within seven days prior to study entry and must have used an effective means of contraception or have been sexually abstinent for at least four weeks prior to the negative serum pregnancy test and through to study entry.

• Female patients of childbearing potential must agree to practice an effective method of birth control during the entire treatment period and for at least three weeks after their last treatment on protocol.

Exclusion Criteria:

• Patients with cutaneous T-cell lymphoma.

• Patients previously treated with ONTAK (DAB389lL-2) or DAB486IL-2.

• Inability to comply with protocol requirements for this study.

• Pregnant women or lactating women who are breast feeding or women planning to become pregnant during the treatment period or three weeks after their last treatment on protocol.

• Serious intercurrent medical illnesses or active infections requiring parenteral antibiotics, which would interfere with the ability of the patient to carry out the treatment program.

• Sero-positive for human immunodeficiency virus (HIV) antibody. History of ongoing Hepatitis B or Hepatitis C infection.

• Another malignancy or history of another cancer with less than five disease-free years (other than resected basal or squamous cell skin cancers or in situ cervical cancer).

• Patients with a known hypersensitivity to ONTAK or any of its components: diphtheria toxin, interleukin-2, or excipients.

• Any investigational agents within one month prior to study entry.

• Prior radiation therapy within four weeks of enrollment or to the only site of evaluable disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Low-grade
• Lymphoma, Non-Hodgkin
• Non-Hodgkin's Lymphoma

Intervention

Drug:
• ONTAK

Locations

Country	Name	City	State
United States	Central Baptist Hospital	Lexington	Kentucky
United States	Hematology and Oncology Services	Metairie	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8.	Complete response: achievement of a complete regression for >4 weeks of all palpable and x-ray demonstrable disease and bone marrow disease. Partial response: response to therapy with a 75% reduction in the greatest diameters of the measurable lesions for >4 weeks and had indeterminate bone marrow biopsy	24 Weeks	No
Secondary	Duration of Response	The duration of response was defined as the time interval from start of the first response (CR or PR) to the time of documented disease progression.	From beginning of response to time of relapse	No
Secondary	Time-to-Treatment Failure		From start of first treatment	No